The present invention relates to novel compounds, pharmaceutical compositions and methods for treating tumors, cancer and hyperproliferative diseases including psoriasis, genital warts and hyperproliferative cell growth diseases, including hyperproliferative keratinocyte diseases such as hyperkeratosis, ichthyosis, keratoderma or lichen planus. These compounds are described according to the chemical structure: ##STR00001## where R.sup.1 is H, OH, F, Cl, Br, I, a C.sub.1-C.sub.6 optionally substituted alkyl or alkenyl group, an optionally substituted aryl group or a ##STR00002## group; R.sub.a is a H, OH, C.sub.1-C.sub.10, optionally substituted alkyl or alkenyl group, an optionally substituted O--(C.sub.1-C.sub.7 alkyl group) or O-aryl group, an amine group which is optionally substituted with at least one C.sub.1-C.sub.10 alkyl group which may be optionally substituted, or a single optionally substituted aryl group, biphenyl group, (C.sub.1-C.sub.6) alkylenearyl group, (C.sub.1-C.sub.6) alkylenebiphenyl group, heteroaryl group, heterocyclic group, (C.sub.1-C.sub.6) alkylene heteroaryl group or (C.sub.1-C.sub.6) alkylene heterocyclic group; R.sup.2 is a ##STR00003## group; R.sub.b is a H, OH, C.sub.1-C.sub.10, optionally substituted alkyl or alkenyl group, an optionally substituted O--(C.sub.1-C.sub.7 alkyl group) or O-aryl group, an amine group which is optionally substituted with at least one C.sub.1-C.sub.10 alkyl group which may be optionally substituted, or a single optionally substituted aryl group, biphenyl group, (C.sub.1-C.sub.6) alkylenearyl group, (C.sub.1-C.sub.6) alkylenebiphenyl group, heteroaryl group, heterocyclic group, (C.sub.1-C.sub.6) alkylene heteroaryl group or (C.sub.1-C.sub.6) alkylene heterocyclic group; R.sup.3 and R.sup.6 are each independently selected from H, OH, F, Cl, Br, I, a C.sub.1-C.sub.6 optionally substituted alkyl or alkenyl group, an optionally substituted aryl group, a carbamate, alkylene carbamate, urethane or alkylene urethane; R.sup.4 is a ##STR00004## group, wherein R.sub.b is as described above; and R.sup.5 is a ##STR00005## group, wherein R.sub.b is as described above, with the proviso that at least one of R.sup.1 and R.sup.2 or R.sup.4 and R.sup.5 contains an R.sub.a or R.sub.b group which is an amine group which is optionally substituted with at least one C.sub.1-C.sub.10 alkyl group which may be optionally substituted, or a single optionally substituted aryl group, biphenyl group, (C.sub.1-C.sub.6) alkylenearyl group, (C.sub.1-C.sub.6) alkylenebiphenyl group, heteroaryl group, heterocyclic group, (C.sub.1-C.sub.6) alkylene heteroaryl group or (C.sub.1-C.sub.6) alkylene heterocyclic group; or a stereoisomer, pharmaceutically acceptable salt, solvate, and polymorph thereof.